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Abstract: The number of cytosine-thymine-guanine (CTG) repeats (‘CTG expansion size’) in the
3′untranslated region (UTR) region of the dystrophia myotonica-protein kinase (DMPK) gene is a
hallmark of myotonic dystrophy type 1 (DM1), which has been related to age of disease onset and
clinical severity. However, accurate determination of CTG expansion size is challenging due to its
characteristic instability. We compared five different approaches (heat pulse extension polymerase
chain reaction [PCR], long PCR-Southern blot [with three different primers sets—1, 2 and 3] and small
pool [SP]-PCR) to estimate CTG expansion size in the progenitor allele as well as the most abundant
CTG expansion size, in 15 patients with DM1. Our results indicated variability between the methods
(although we found no overall differences between long PCR 1 and 2 and SP-PCR, respectively).
While keeping in mind the limited sample size of our patient cohort, SP-PCR appeared as the most
suitable technique, with an inverse significant correlation found between CTG expansion size of the
progenitor allele, as determined by this method, and age of disease onset (r = −0.734, p = 0.016).
Yet, in light of the variability of the results obtained with the different methods, we propose that an
international agreement is needed to determine which is the most suitable method for assessing CTG
expansion size in DM1.
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1. Introduction
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder with an autosomal dominant
inheritance pattern. DM1 is caused by unstable expansion of CTG repeats in the 3′ untranslated
(UTR) region of the dystrophia myotonica-protein kinase (DMPK) gene [1]. Non-affected individuals
usually have 5 to 35 CTG repeats, with carriage of 35 to 49 repeats, leading to a “pre-mutational”
phenotype that is not usually associated with clinical manifestations. In turn, patients with DM1
typically have more than 50 CTG repeats in the blood, and sometimes up to several thousands [2].
Furthermore, because CTG expansion is highly unstable and prone to increase in these patients,
an eventual decrease (or ‘contraction’) in the number of CTG repeats is typically biased toward
further expansion in the context of DNA replication, recombination, transcription and/or repair [3–7].
Consequently, CTG expansion shows a characteristic somatic mosaicism [8].
Determination of the actual number of CTG repeats is complicated by the immense length of
the expanded alleles as well as by the highly stable secondary structures that are created inside the
repetitive guanine-cytocine (GC)-rich sequence. In addition, it is possible to underestimate rare mutant
molecules in both germline and somatic cells. Accurate assessment of CTG expansion size is important
in patients with DM1. Indeed, the number of CTG repeats can be inversely and directly related with
age of disease onset and clinical severity, respectively [9,10]. Although different approaches have been
described to assess CTG expansion size in patients with DM1 [5,11–15], some methodological issues
remain to be solved, mainly related to the inherent repeat instability and technical difficulties when
amplifying long CTG fragments.
It was therefore the purpose of this study to compare the number of CTG repeats (‘expansion size’)
of the progenitor allele and the mode allele between five different assays using three different methods:
(i) heat pulse extension (HPE)-polymerase chain reaction (PCR); (ii) long PCR (LPCR)1-Southern blot
(SB); (iii) LPCR2-SB; (iv) LPCR 3-SB; and (v) small pool (SP)-PCR. The rationale behind this work was
to determine whether the different methodologies that are currently available yield comparable results,
so that it is necessary—or not—to come to a consensus as to which methodology should be used.
2. Materials and Methods
2.1. DNA Extraction and Subjects
This study was approved by the Ethics Committee of the University Hospital Germans Trias
i Pujol (Badalona, Spain) and was performed in agreement with the Declaration of Helsinki for
Human Research in 1975. All subjects signed a written informed consent to participate in the study.
Total genomic DNA was obtained from peripheral blood in 15 patients with DM1 and 10 controls,
as previously described [16]. Diagnosis of DM1 was confirmed by triplet primed-PCR, as reported
elsewhere [17]. In controls, CTG number in both DMPK alleles was assessed by Sanger sequencing.
2.2. Heat Pulse Extension-PCR
First, we amplified the genomic DNA from patients and controls using HPE-PCR, as described
elsewhere [13]. Unlike conventional PCR, in which the extension step is performed at a constant
temperature, HPE-PCR includes multiple heat pulses in the extension step. Heat pulses temporarily
destabilize the secondary structures formed in the long GC-rich repetitive sequence, thereby improving
the extension efficiency and the amplification of the long expansions. The technique was carried out
using the same PCR conditions, reagents, the equivalent taq polymerase (Phusion High-Fidelity DNA
Polymerase, Thermo Fisher Scientific; Waltham, MA, USA) and the same thermocycler (GeneAmp 9700
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thermal cycler, Applied Biosystems, Foster City, CA, USA) as the Orpana et al. study [13]. The sizing of
the CTG expansion was performed in a 1% agarose gel using the molecular ladder NZYDNA Ladder
III (NZYTech, Lisboa, Portugal).
2.3. Long PCR-Southern Blot
The DNA samples (100 ng per reaction) were amplified with three different primer sets in a
LPCR: (i) DM102 and DM101 (LPCR1); (ii) MDY1D and SOMY4R (LPCR2); (iii) MDY1D and DM1rev
(LPCR3). We used the LongAmp® Taq PCR Kit (New England BioLabs, Ipswich, MA, USA) and the
GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA). The set conditions for
each of the three LPCR methods were as follows: initial denaturation at 94 ◦C for 4 min, followed by
35 cycles of denaturation at 94 ◦C for 30 s, and annealing–extension at 65 ◦C for 7 min. Final extension
was performed at 65 ◦C for 10 min. Subsequently, LPCR products were analyzed using SB. In brief,
all LPCR products were electrophoresed in a 0.8% agarose gel at 80V for 90 min, and transferred to a
nylon membrane (Roche; Basel, Switzerland) after gel washing with an acid solution (250 mM HCl) for
15 min, a basic solution (0.5M NaOH) for 30 min, and a neutralizing solution (0.5 M Tris-HCl, pH = 7.5,
1.5 M NaCl) for 30 min. DNA was fixed to the membrane by incubation for 1 h 15 min at 65 ◦C.
We used a concentration of 10 pmol/mL DIG-labeled LNA probe (5′-gcAgCagcAgCagCagcAgca-3′,
where capital letters indicate LNA nucleotides) to hybridize the membrane for 3 h at 70 ◦C. Expansion
size was determined by chemiluminescence yielded by the binding of alkaline phosphatase-conjugated
to anti-DIG antibody and CDP-Star substrate, according to the manufacturer’s instructions (Roche).
2.4. Small Pool-PCR
As opposed to the conventional PCR-Southern Blot, the SP-PCR technique uses small amounts of
input DNA, allowing the study of single genomic equivalents, which are represented as single bands
in the gel. SP-PCR was carried out using 300 pg of DNA in four replicates per sample, in order to
study a representative repeat length distribution of the sample. We used the flanking primers DM-C
and DM-DR as previously described [5,18], using a custom PCR Master Mix (Thermo Fisher Scientific;
Waltham, MA, USA) supplemented with 69 mM 2-mercaptoethanol, and Taq polymerase Thermus
aquaticus (Sigma-Aldrich; Gillingham, UK) at 1 unit per 10 µL. All reactions were supplemented with
5% DMSO and the annealing temperature was 63.5 ◦C. DNA fragments were resolved by electrophoresis
on a 1% agarose gel, SB was hybridized using GE Healthcare Nylon Hybond N Membrane (Thermo
Fisher Scientific; Waltham, MA, USA) as described [5,18], and autoradiographic images were scanned.
For LPCR-SB and SP-PCR, the CTG size of the progenitor allele and the mode allele (i.e., yielding
the most intense band signal) of each patient were estimated by comparison against the molecular
weight ladder, using GelAnalyzer 19.1 software. The length of the flanking CTG region of each PCR
was subtracted for all the estimated CTG lengths.
2.5. Statistical Analysis
After checking that the data followed a normal distribution with the Kolmogorov–Smirnov test,
we used a repeated-measures one-way analysis of variance (ANOVA) test for performing within-subject
comparisons of the mean values of CTG expansion size of the progenitor allele and of the mode allele,
respectively, obtained with the different methods. We also calculated the Pearson correlation between
(i) the results yielded with the different methods, and (ii) the results obtained with each method and
the age of disease onset, the Muscular Impairment Rating scale (MIRS), and the modified Rankin Scale
(mRS), respectively, in the 15 DM1 patients. All statistical analyses were conducted using a statistical
software package (SPSS 23), setting the significance level at α = 0.05.
3. Results
A total of five primer sets were used (Figure 1), corresponding to the five different methods to measure
CTG expansion size in our patients. All the primers were located outside the CTG repeat expansion.
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The name of each primer and its sequence are shown in Table 1. The length of each PCR product varied
from 106 to 324 base pairs, depending on the primer set used (plus the number of CTG repeats for each
patient) (Table 1). Thus, the differences in PCR amplification among the techniques were small.
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Figure 1. DMPK gene and location of the primer sets. Primers sets are indicated by the name of the
technique and identified with a different background color. All of them were located outside the CTG
expansion. LPCR2 and LPCR3 share the same fo ward pri r. The dista ce (bp) etwee primers is
also indicated. Abbreviations: F—forward; HPE-PCR—heat pulse ext nsion-polymerase chain reaction;
LPCR—long polymerase chain re ction; R—r verse; SP-PCR—small pool polymerase chain reaction.
Some technical difficulties were found with the HPE-PCR method. Although the technique
worked in our hands, the results we obtained were inconsistent (Figure S1A) and thus, not comparable
to previously published results [13]. Eight controls amplified smears that were similar to the ones
found in patients—the status of control in our analysis is guaranteed, since prior to this analysis, we
measured CTG alleles by sequencing. Thus, the cause of these unexpected smears is not apparent
because they were unrelated to the CTG expansion in the study controls. As such, these data were
excluded from statistical analyses. The results for all the methods, but HPE-PCR, are shown in Figure 2.
Genes 2020, 11, x FOR PEER REVIEW 6 of 10 
 
Some technical difficulties were found with the HPE-PCR method. Although the technique 
worked in our hands, the results we obtained were inconsistent (Figure S1A) and thus, not 
comparable to previously published results [13]. Eight controls amplified smears that were similar to 
the ones found in patients—the status of control in our analysis is guaranteed, since prior to this 
analysis, we measured CTG alleles by sequencing. Thus, the cause of these unexpected smears is not 
apparent because they were unrelated to the CTG expansion in the study controls. As such, these 
data were excluded from statistical analyses. The results for all the methods, but HPE-PCR, are shown 
in Figure 2. 
 
Figure 2. CTG expansion size of the progenitor allele (A) and the mode allele (B) for each technique. 
The progenitor allele was estimated by the lowest signal yielded after WT range for LPCR-SB, and by 
the most frequent lower band present in the samples for SP-PCR. Mode allele was estimated by the 
more intense signal yielded by LPCR and the most abundant band for SP-PCR. Data for heat pulse 
extension-polymerase chain reaction are not shown owing to the inconsistency of the results. All valid 
individual data within the detection limit (2000 CTGs) are shown(different color per patient). 
Normality was analyzed with the Kolmogorov–Smirnov test and we used a repeated-measures one-
way analysis of variance (ANOVA) test for performing within-subject comparisons between methods. 
No significant group (or ‘method’) effect was found for the progenitor allele (p = 0.112) or the mode 
allele (p = 0.653). Mean and SD values are shown only for those methods included in the within-subject 
analyses (i.e., LPCR1, LPCR2 and SP-PCR). A significant Pearson correlation was found between the 
progenitor allele of LPCR1 and LPCR (indicated by an *symbol in the Figure, r = 0.983 [95% confidence 
interval (CI) 0.940 to 0.996], p < 0.0001). Y-axis scale is segmented from 500 CTGs to 2000 CTGs, 
representing 25% of the total length axis. Abbreviations: LPCR—long polymerase chain reaction; SP-
PCR—small pool polymerase chain reaction. 
We also found problems with the LPCR-SB technique, which did not allow amplification of the 
CTG expansion in some patients (2 for LPCR1-SB and LPCR2-SB, respectively, and 11 for LPCR3-SB). 
Thus, based on the small amount of individual data points obtained with LPCR3-SB, we also 
excluded these data from statistical analyses. In LPCR, the amplified product in patients appeared 
sometimes as a high smear (Figure S1B), probably due to a mobility impairment in long 
amplifications of highly concentrated DNA (i.e., 100 ng in the final PCR reaction). Attending to the 
juvenile-classical phenotype of our patients, we established a detection limit of 2000 CTGs. In this 
context, three CTG sizes of the mode allele in LPCR1-SB were excluded from the study. None of the 
progenitor expansions surpassed the 2000 CTG-limit. SP-PCR amplified the CTG expansion of all the 
patients at the first attempt except for two of them—in whom, we had to repeat the amplification in 
order to correctly detect and quantify CTG expansion. Representative results of SP-PCR can be seen 
in Figure S1C. 
LPCRs yielded shorter progenitor alleles and higher mode alleles compared to SP-PCR (Figure 
2). No significant group effect was found with the one-way repeated-measures ANOVA between the 
Figure 2. CTG expansion size of the progenitor allele (A) and the mode allele (B) for each technique.
The progenitor allele was estimated by the lowest signal yielded after WT range for LPCR-SB, and by
the most frequent lower band present in the samples for SP-PCR. Mode allele was estimated by the
more intense signal yielded by LPCR and the most abundant band for SP-PCR. Data for heat pulse
extension-polymerase chain reaction are not shown owing to the inconsistency of the results. All valid
individual data within the detection limit (2000 CTGs) are shown(different color per patient). Normality
was analyzed with the Kolmogorov–Smirnov test and we used a repeated-measures one-way analysis
of variance (ANOVA) test for performing within-subject comparisons between methods. No significant
group (or ‘method’) effect was found for the progenitor allele (p = 0.112) or the mode allele (p = 0.653).
Mean and SD values are shown only for those methods included in the within-subject analyses
(i.e., LPCR1, LPCR2 and SP-PCR). A significant Pearson correlation was found between the progenitor
allele of LPCR1 and LPCR (indicated by an *symbol in the Figure, r = 0.983 [95% confi ence interval
(CI) 0.940 to 0.996], p < 0.0001). Y-axis scale is segmented from 500 CTGs to 2000 CTGs, representing
25% of the total length axis. Abbreviations: LPCR—long polymerase chain reaction; SP-PCR—small
pool polymerase chain reaction.
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Table 1. Techniques and primer sets used in this study.
Technique bp of the Amplified Fragment(without CTG Expansion) Primer Pair Name Sequence 5
′—3′ Reference
HPE-PCR 324
F DMKf GCCAGTTCACAACCGCTCCGAGCGTGGGTC Orpana et al. [13]
R DMKr ACGCTCCCCAGAGCAGGGCGTCATGC Orpana et al. [13]
LPCR1-SB 112
F DM102 GAACGGGGCTCGAAGGGTCCTTGT Brook et al. [1]
R DM101 CTTCCCAGGCCTGCAGTTTGCCCATCCA Brook et al. [1]
LPCR2-SB 144
F MDY1D GCTCGAAGGGTCCTTGTAGCCG Siciliano et al. [15]
R DM1REV GTGCGTGGAGGATGGAAC Radvansky et al. [17]
LPCR3-SB 262
F MDY1D GCTCGAAGGGTCCTTGTAGCCG Siciliano et al. [15]
R SOMY4R CGGGTTTGGCAAAAGCAAATTTCCCGA Musova et al. [19]
SP-PCR 106
F DM-C AACGGGGCTCGAAGGGTCCT Monckton et al. [5];Gomes-Pereira et al. [18]
R DM-DR CAGGCCTGCAGTTTGCCCATC Monckton et al. [5];Gomes-Pereira et al. [18]
Abbreviations: bp—base pairs; F—forward; HPE-PCR—heat pulse extension-polymerase chain reaction; LPCR—long polymerase chain reaction; R—reverse; SP-PCR—small pool
polymerase chain reaction.
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We also found problems with the LPCR-SB technique, which did not allow amplification of the
CTG expansion in some patients (2 for LPCR1-SB and LPCR2-SB, respectively, and 11 for LPCR3-SB).
Thus, based on the small amount of individual data points obtained with LPCR3-SB, we also excluded
these data from statistical analyses. In LPCR, the amplified product in patients appeared sometimes as
a high smear (Figure S1B), probably due to a mobility impairment in long amplifications of highly
concentrated DNA (i.e., 100 ng in the final PCR reaction). Attending to the juvenile-classical phenotype
of our patients, we established a detection limit of 2000 CTGs. In this context, three CTG sizes of the
mode allele in LPCR1-SB were excluded from the study. None of the progenitor expansions surpassed
the 2000 CTG-limit. SP-PCR amplified the CTG expansion of all the patients at the first attempt except
for two of them—in whom, we had to repeat the amplification in order to correctly detect and quantify
CTG expansion. Representative results of SP-PCR can be seen in Figure S1C.
LPCRs yielded shorter progenitor alleles and higher mode alleles compared to SP-PCR (Figure 2).
No significant group effect was found with the one-way repeated-measures ANOVA between the three
techniques with analyzable data (i.e., LPCR1, LPCR2 and SP-PCR) for the within-subject comparison
of CTG expansion size of the progenitor (p = 0.112) or mode allele (p = 0.653). A significant, strong
correlation was found between LPCR1-SB and LPCR2-SB for CTG expansion size of the progenitor
allele (r = 0.983 [95% confidence interval (CI) 0.940 to 0.996], p < 0.0001). However, no other significant
correlation was found for the results obtained with LPCR1-SB, LPCR2 or SP-PCR, respectively
(all p > 0.05). We further studied possible correlations with age of disease onset, MIRS and mRS scale.
We found an inverse, significant correlation between CTG expansion size of the progenitor allele as
determined by SP-PCR, and age of disease onset (Figure 3).
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Figure 3. Correlation between the age of disease onset (years) and the CTG expansion size of the
progenitor allele obtained through SP-PCR. The 95% confidence interval for the Pearson correlation
coefficient was −0.933 to −0.1940 (r = −0.734, p = 0.016).
4. Discussion
Although no significant group effect was found with the one-way repeated-measures ANOVA
between LPCR1/2 and SP-PCR, our results indicate that there is variability in the number of CTG
repeats for a given patient depending on the CTG sizing method. HPE-PCR showed results that were
difficult to interpret. Additionally, LPCR3 did not allow amplification of most of the DNAs in the
patients. However, the fact that LPCR1 and LPCR-2 did yield some valid results suggests that LPCR-SB
might be more sensitive to parameters such as the quality of the input DNA, which is not the case
for the SP-PCR technique. SP-PCR was the only technique that enabled amplification of all DNAs
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from the patients and in fact, was the only one yielding a result that was correlated with an important
phenotype trait of DM1—age of disease onset.
While a strong correlation was found between LPCR1-SB and LPCR2-SB for CTG expansion
size of the progenitor allele, no other significant correlation was found. LPCR1/2-PCR yielded lower
progenitor sizes and higher mode sizes than SP-PCR. LPCR-SB approaches usually show the expanded
alleles as diffuse smears rather than discrete bands, due to the high input of DNA plus the somatic
instability of the mutation [20]. This fact hinders differentiation of the progenitor allele size from
possible contractions of the repeat. The number of PCR cycles may also affect the results—35 cycles are
used in LPCR vs. 28 for SP-PCR—since a high number of cycles facilitates the amplification of shorter
products, whereas longer products may be not favored. Moreover, the number of PCR cycles increases
PCR slippage, tending to shorten the products. These phenomena could explain that these techniques
yielded lower progenitor sizes than SP-PCR. By contrast, SP-PCR—which amplifies only small pools of
input DNA—shows discrete bands that allow for a detailed analysis of the mutational spectrum and
allele size distribution [18]. As such, this technique enables a better detection and estimation of the
progenitor allele from post-contractions of the repeat. In three of the 15 patients, LPCR1-SB yielded
some intense signals running high in the gel which, when measured, showed sizes above 2000 CTG
repeats. Because the amount of input DNA is high (100 ng) in the different LPCR methods, the DNA
mobility in the gel can be impaired, spreading out and yielding a signal that is higher than the actual
CTG expansion size. Therefore, when using these LPCR-SB techniques, it would be necessary to set up
a threshold for measuring CTG size in the detected smears.
It would be interesting to determine how novel, recently described technologies for CTG
sizing [11,12] compare to the methods we assessed here. The sizing kit used by Leferink et al.,
was based on tripled repeat primed PCR, which is a robust and accurate technique to determine the
presence of a CTG expanded allele [11]. However, the sizing of the repeat was limited in their study,
set at 180 CTG repeats. In this regard, the most frequent DM1 form, the classical adult form, is usually
associated with CTG repeats ranging from fifty to thousands. In fact, more than 70% of the samples in
our study had more than 180 CTG repeats. Thus, although the kit reported in the Leferink et al. study
would seem very useful for accurate DM1 diagnosis, it would not be suitable to size CTG expansion.
In the study by Malbec et al., repeat sizing was performed with a lab-on-chip system that concentrates,
separates, and detects DNA fragments in a very short time (actually, less than 5 min) from femtomolar
concentrations of PCR-amplified DNAs [12]. Although this system appears as a good alternative to
the sizing methods that we assessed, its accuracy would depend on the design of the primers used
and the PCR amplification cycle. Furthermore, it would be also necessary to test some PCR designs
in order to determine to what extent they are similar. Furthermore, since the chip presented in the
Malbec et al. study can detect expansions up to 4Kb, it would have limitations to size samples from
patients with congenital DM1. In fact, although their results were promising, only two DM1 blood
samples were tested with the new technology, and as such, the interference of somatic mosaicism in
CTG sizing remains to be analyzed.
Some studies have described that CTG repeat number can be a good indicator of disease onset [14].
In this regard, we further explored whether the different sizing results were related to the age of
disease onset, finding a significant correlation for the SP-PCR method only. These results are overall in
accordance with previous studies reporting a correlation between progenitor allele length measured by
SP-PCR and both age of disease onset and clinical severity [10,21], although we found no correlation
with MIRS or mRS. Progenitor allele length is the major modifier of age of disease onset, and as such,
it is very important to use an accurate method for its determination. Concerning the lack of correlation
with MIRS and mRS scales, CTG sizes in blood may be poor representatives of muscle status. Thus,
future research in this field might study CTG in muscle cells.
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5. Conclusions
Our study suggests that, besides the somatic mosaicism caused by CTG repeat instability and
the inherent technical difficulties in assessing CTG expansion, there is overall heterogeneity among
the different methods that are currently available, which makes it difficult to rely on them as valid
predictors of disease phenotype. International agreement is needed to determine which is the most
suitable methodology to characterize CTG expansion size in patients with DM1.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/7/757/s1.
Figure S1: Representative results of the three different methods: HP-PCR, LPCR-SB and SP-PCR. (A) HP-PCR gel.
Three patients and three controls are shown as representative results of HP-PCR. Controls showed similar signals
to the ones found in patients. As such, these data were excluded from statistical analysis. (B) LPCR-SB gel showing
the amplification results of the three primer sets: (1) DM102 and DM101 (LPCR1); (2) MDY1D and SOMY4R
(LPCR2); and (3) MDY1D and DM1rev (LPCR3). Three patients and one control are shown. With this technique,
we could not amplify the CTG expansion in some patients (two for LPCR1-SB and LPCR2-SB, respectively, and 11
for LPCR3-SB). The amplified product in patients appears as high smears, probably due to highly concentrated
DNA (100 ng). (C). SP-PCR gel. Two patients and one control are shown, with four replicates per sample. Using
small amounts of input DNA (300 pg), the technique allows us to study single genomic equivalents, which are
amplified individually and further separated in the gel. Therefore, the gel shows discrete bands corresponding to
individually CTG tracts of different lengths.
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